BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Bank of America Merrill Lynch
|Target Hit|| Long (1Y)
Bank of America Merrill Lynch downgrades Sun Pharma to neutral
Earnings pace to decelerate as some niche opportunities may face incremental competition. 50 per cent of FY14 profit is vulnerable to price competition. Valuations leave limited room for upside. Target Rs 670.